June 06, 2019 Industry news
Now that the Falsified Medicines Directive has come into play, understanding what this means for pharmaceutical manufacturers, pharmacists in acute and community settings, and, ultimately, the impact on patient safety is important.
In recent years, the number of falsified and counterfeit medications infiltrating the supply chain has become a growing problem for global health organisations and pharmaceutical manufacturers. Not only have there been cost implications, but there are also huge risks to patient safety.
Have a look at our dedicated FMD information page for further details or contact our healthcare team.